4070-90-0Relevant articles and documents
NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Page/Page column 128, (2015/06/25)
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.
Inhibition of monoamine oxidase by the R and S enantiomers of N-N-methyl-3-butyn-2-amine
Dostert, P,O'Brien, EM,Tipton, KF,Meroni, M,Melloni, P,Benedetti, M Strolin
, p. 45 - 52 (2007/10/02)
The chemical synthesis of the R-(+)- and S-(-)-enantiomers of N-N-methyl-3-butyn-2-amine is described.These compounds are derivatives of the mechanism-based irreversible monoamine oxidase inhibitor clorgyline in which a meth